FindTrial
Sign In

UV1

BIOLOGICAL6 trials

Sponsors

Vestre Viken HF, Nordic Society Of Gynaecological Oncology Clinical Trial Unit, Ultimovacs ASA, Martin-Luther-Universität Halle-Wittenberg, Vestre Viken Hospital Trust

Conditions

Head and Neck Squamous Cell CarcinomaMalignant MelanomaNSCLC Stage IVNSCLC, Stage IIIOncologyOvarian canceradvanced or metastatic non-small cell lung cancer

Phase 1

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
CompletedNCT03538314
Ultimovacs ASAMalignant Melanoma
Start: 2018-07-09End: 2024-06-15Updated: 2024-08-22

Phase 2

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
CompletedNCT04382664
Ultimovacs ASAMalignant Melanoma
Start: 2020-05-27End: 2024-04-10Updated: 2025-01-14
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
NCT05075122
Martin-Luther-Universität Halle-WittenbergHead and Neck Squamous Cell Carcinoma
Start: 2021-08-02End: 2025-02-28Target: 75Updated: 2022-03-09
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
RecruitingNCT05344209
Vestre Viken Hospital TrustNSCLC, Stage III, NSCLC Stage IV, Oncology
Start: 2022-08-12End: 2027-07-01Target: 138Updated: 2023-11-09
A randomized, phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer
CompletedCTIS2022-502437-25-00
Vestre Viken HFadvanced or metastatic non-small cell lung cancer
Start: 2022-08-15End: 2024-09-12Target: 141Updated: 2024-12-04
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
Not yet recruitingCTIS2024-516327-14-00
Nordic Society Of Gynaecological Oncology Clinical Trial UnitOvarian cancer
Target: 188Updated: 2025-10-02

Related Papers

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer
npj Precision Oncology2025-08-053 citations
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.
2025-04-112 citations
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
Journal of Clinical Oncology2024-06-054 citations
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
Frontiers in Oncology2024-02-0711 citations
156TiP The LUNGVAC-study: A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first-line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Immuno-Oncology Technology2023-12-01
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
2022-09-1117 citations
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
2021-05-3123 citations
A phase I clinical trial investigating the telomerase vaccine UV1 in combination with pembrolizumab in patients with advanced melanoma.
Journal of Clinical Oncology2021-05-204 citations
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Frontiers in Immunology2021-05-1140 citations